Although further research on the role of the PD-1/PD-L1 pathway in laryngeal tumors is necessary, the presented reports are promising and may contribute to considerations on the introduction of targeted immunotherapy, with anti-PD1 and anti-PD-L1 monoclonal antibodies, in the regular treatment of this group of tumors. The gene discussed is PDCD1; the disease is laryngeal neoplasm.